Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study

Table 2 Tumor responses for the patients in matched cohort

Response	Overall tumor			Intrahepatic tumor			Vascular tumor thrombus
Response	TKI-I group (n = 51)	TKI group (n = 51)	P	TKI-I group (n = 51)	TKI group (n = 51)	P	TKI-I group (n = 42)	TKI group (n = 36)	P
CR, n (%)	1 (2.1)	1 (2.1)		2 (4.2)	1 (2.1)		13 (36.1)	0 (0.0)
PR, n (%)	32 (66.7)	15 (31.3)		31 (64.6)	16 (33.3)		16 (44.4)	5 (12.5)
SD, n (%)	10 (20.8)	16 (33.3)		11 (22.9)	17 (35.4)		4 (11.1)	22 (55.0)
PD, n (%)	5 (10.4)	16 (33.3)		4 (8.3)	14 (29.2)		3 (8.3)	13 (32.5)
ORR, %	68.8	33.3	0.001	68.8	35.4	0.001	80.6	12.5	< 0.001
DCR, %	89.6	66.7	0.007	91.7	70.8	0.009	91.7	67.5	0.010

TKI-I tyrosine kinase inhibitor combined with iodine-125 seed brachytherapy, TKI tyrosine kinase inhibitor, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate

ISSN: 1470-7330